U.S. Weighs Preserving Most Chinese Drug Licensing Deals Under New Investment Rules

Posted 9/29/26

Eli Lilly’s new collaboration with China’s InnoCare Pharma underscores the commercial stakes as the Trump administration considers whether to preserve most pharmaceutical licensing deals under forthcoming outbound investment rules.

This item is available in full to subscribers.

Please log in to continue

Log in